
10/506,975 Page 4



G1 CH2,0

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 15:25:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO 124

PROJECTED ANSWERS: 1 TO 80

L21 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 15:25:23 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 3 ANSWERS

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL

> ENTRY SESSION

FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 15:25:34 ON 16 DEC 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

<12/16/2005> Habte 10/506,975 Page 5

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Dec 2005 VOL 143 ISS 26 FILE LAST UPDATED: 15 Dec 2005 (20051215/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13

L4 3 L3

=> d ibib abs hitstr tot

10/506,975

Page 6

L4 ANSWER 1 OF 3
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:
INVENTOR(S):

PATENT ASSIGNEE(S):

PATENT ASSIGNEE(S):

COURCE:

COURC

DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2003076639 A1 20030918 W0 2003-JP2633 2003030 W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CI CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GB, GE, GB, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, L	
WO 2003076639 A1 20030918 WO 2003-JP2633 2003030 W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CI CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, G GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, L	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, Cl CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, L	-
CO, CR, CU, C2, DE, DK, DM, D2, EC, EE, ES, FI, GB, GD, GE, G GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, L	6
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, L	N,
	Ħ,
	S,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PI	H,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, T	Z,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, B'	Y,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, E	5,
FI. FR. GB. GR. HU. IE. IT. LU. MC. NL. PT. SE, SI. SK. TR. BI	F
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1489187 A1 20041222 EP 2003-710258 2003030	6
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, P	r,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
US 2005124050 A1 20050609 US 2003-506975 20030309	6
PRIORITY APPLN. INFO.: JP 2002-63046 A 2002030	8
WO 2003-JP2633 W 2003030	6
GI	

AB The osteoclast differentiation inhibitors (I: X = 0 or CH2; R = 0H when X = 0, and R = H when X = CH2) are manufactured with Cunninghamella and by chemical

synthesis. Manufacture of F-1490 by culturing Cunninghamella, and chromatog.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:280574 CAPLUS
DOCUMENT NUMBER: 139:270769
IITLE: (CM0201, a new inhibitor of osteoclastogenesis from Cunninghamella sp. F-1490. II. Structure determination and synthesis
Someno. Tetsuyas Inoue, Hiroyukir Kumagai, Hiroyukir Ishizuka, Masaakir Takeuchi, Tomio Institute for Chemotherapy, H.C.R.F., Shizuoka, 410-0301, Japan
SOURCE: Journal of Antibiotics (2003), 56(3), 214-218
CODEN: JANTAJ, ISSN: 0021-8820
DOCUMENT TYPE: Journal
LANGUAGE: Japan Antibiotics Research Association
Journal AB ICN0201 (1), a new inhibitor of murine osteoclastogenesis in culture was isolated from a fermentation broth of Cunninghamella sp. F-1490. The structure of ICM0201 was determined to be (35, 10aR) -3, 4a-dihydroxy-2, 3, 4, 4a-tetrahydro-2H-pyrano(3,2-b]benzo(e] morpholine-9-carboxylic acid by spectroscopic analyses and chemical studies. The structure of 1 is unique in that the tricycle ring system is composed of aminal and hemiacetal bonds.

T 581092-44-6F, ICM 2021
RL: NFO (Natural product occurrence): PRP (Properties): RCT (Reactant): SFN (Synthetic preparation): HIW (Therapeutic use): BIOL (Biological study): OCCU (Occurrence): PREF (Preparation): RACT (Reactant or reagent): USES (Uses)

(csteoclastogenesis inhibitor ICM0201: isolation from Cunninghamella, structure determination and preparation)

RN 581092-44-6 CAPLUS

CN Pyrano(3,2-b) [1,4]benzoxzine-9-carboxylic acid, 2,3,4,4a,10,10a-hexahydro-3,4a-dihydroxy-, (3S,10aR)- (9CI) (CA INDEX NAME)

607376-23-8F, (+)-ICH 0201
RL: PRP (Properties): SPN (Synthetic preparation): PREP (Preparation)
(osteoclastogenesis inhibitor ICH0201: isolation from Cunninghamella,
structure determination and preparation)
607376-23-8 CAPLUS
Pyrano[3,2-b][1,4]benzoxazine-9-carboxylic acid, 2,3,4,4a,10,10a-bexahydro-3,4a-dihydroxy-, (3R,10a5)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued) isolation of F-1490 from feram. filtrate were shown. Also shown was chem. synthesis of F-1490A from 3-hydroxyanthranilic acid and 1,2-cyclohexandione in the presence of sodium borohydride. The physiol. and morphol. characteristics of Cunninghamella and physicochem. characteristics of F-1490 were also given.

Sal092-44-6F, Osteoclast differentiation inhibitor F-1490
RL: BPN (Blosynthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (osteoclast differentiation inhibitors manufacture with Cunninghamella) \$\$1092-44-6 CAPLUS
Pyrano[3,2-b][1,4]benzoxazine-9-carboxylic acid, 2,3,4,4a,10,10a-hexabydro-3,4a-dihydroxy-, (35,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

593253-87-3P, Osteoclast differentiation inhibitor F-1490A
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
(osteoclast differentiation inhibitors manufacture with Cunninghamella)
593253-87-3 CAPLUS
H-Phenoxazine-9-carboxylic acid, 2,3,4,4a,10,10a-hexahydro-4a-hydroxy(9CI) (CA INDEX NAME)

Currently available stereo shown.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

REFERENCE COUNT

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/506,975

Page 7

L4 ANSYER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:280573 CAPLUS
11TLE: 2003:280573 CAPLUS
11TLE: 10M0201, a new inhibitor of osteoclastogenesis from Cunninghamella sp. F-1490. I. Taxonomy, fermentation, isolation and biological activities
AUTHOR(S): Incue, Hiroyukir Kumagai, Hiroyukir Osono, Michyuo Hatsufuji, Motkov Sameshima, Tomohiro Kawamura, Naotor Someno, Tetsuyar Ishizuka, Hasaakir Takeuchi, Tomio

Hatsufuji, Motoko Sameshima, Tomohiron Kawamura,
Naotor Someno, Tetsuya, Ishizuka, Hasaaki Takeuchi,
Tomio

CORPORATE SOURCE: Institute for Chemotherapy, M. C. R. F., Shizuoka,
410-0301, Japan

SOURCE: Journal of Antibiotics (2003), 56(3), 209-213

CODEN: JANTAJ, ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In the course of screening for inhibitors of osteoclastogenesis, a new
substance designated as ICM0201 was isolated from a fermentation broth of

Cunninghamella sp. F-1490, ICM0201 inhibited the formation of osteoclasts

in mouse bone marrow cells with an IC50 value of 0.78 µg/mL and showed

weak cytotoxicity against bone marrow cells.

IT 581092-44-6F, ICM 0201

RL: ADV (Adverse effect, including toxicity), BPN (Biosynthetic
preparation), PAC (Pharmacological activity), TRU (Therapeutic use); BIOL

(Biological study), PREP (Preparation), USES (Uses)

(ICM020 isolation from Cunninghamella, osteoclastogenesis inhibition,
and cytotoxicity against tumor cell lines)

RN 581092-44-6 CAPLUS

CN Fyrano(3,2-b)[1,4]benzoxazine-9-carboxylic acid, 2,3,4,4a,10,10a-hexahydro3,4a-4dhydroxy-, (3S,10aR)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT 21